Vise Technologies Inc. Invests $548,000 in Insulet Corporation $PODD

Vise Technologies Inc. bought a new position in Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,600 shares of the medical instruments supplier’s stock, valued at approximately $548,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PODD. E Fund Management Co. Ltd. acquired a new position in Insulet in the second quarter worth approximately $336,000. Aurora Investment Counsel acquired a new stake in shares of Insulet during the 2nd quarter valued at $2,234,000. West Family Investments Inc. acquired a new stake in shares of Insulet during the 2nd quarter valued at $327,000. NewEdge Wealth LLC bought a new stake in shares of Insulet during the 2nd quarter worth $517,000. Finally, Empirical Asset Management LLC bought a new stake in shares of Insulet during the 2nd quarter worth $368,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: CEO Ashley McEvoy purchased 1,100 Insulet shares at an average price of $147.47, an investment of approximately $162,200. The transaction increased her direct holdings by about 5% and may signal management confidence after the stock’s substantial decline. Insulet CEO share purchase article
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Levi & Korsinsky, and others—are soliciting investors who purchased PODD securities during periods generally spanning February 21, 2025, through May 26, 2026. Investors have until August 31, 2026, to seek appointment as lead plaintiff. These announcements largely repeat existing litigation information rather than represent new operating developments. Rosen Law Firm Insulet deadline article
• Negative Sentiment: The lawsuit-related releases allege that Insulet and certain officers violated federal securities laws by failing to disclose issues associated with two voluntary Medical Device Corrections involving Omnipod insulin-delivery systems. The allegations reportedly concern systemic manufacturing defects and potential investor losses; they have not been proven in court. Continued legal publicity increases regulatory, financial, and reputational uncertainty for Insulet and is likely the main reason investor sentiment remains weak. Levi and Korsinsky Insulet class action article

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PODD. Weiss Ratings cut Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Sanford C. Bernstein reduced their target price on Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Bank of America decreased their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Royal Bank Of Canada dropped their price target on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, Stifel Nicolaus cut their price objective on Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Insulet has an average rating of “Hold” and a consensus price target of $195.40.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.36% of the company’s stock.

Insulet Trading Down 1.8%

NASDAQ PODD opened at $145.42 on Tuesday. The firm’s 50 day moving average price is $154.61 and its two-hundred day moving average price is $183.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The stock has a market cap of $10.08 billion, a price-to-earnings ratio of 27.18, a PEG ratio of 1.17 and a beta of 1.10.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.